Yayın:
Optimization of CHARMM force field parameters of a prostate cancer drug enzalutamide

Yükleniyor...
Küçük Resim

Kurum Yazarları

Item type:Araştırmacı/Yazar,
Baday, Sefer
Docent

Danışman

Bölüm / Program

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Elsevier BV

Türü

Araştırma Projeleri

Akademik Birimler

Dergi Sayısı

Özet

Enzalutamide is the most recent and potent clinically available drug molecule used to treat castration-resistant metastatic prostate cancer patients. In the presence of certain mutations on the Androgen receptor, enzalutamide fails to function as an antagonist. The molecular mechanism of this resistance has not been understood clearly. Molecular Dynamics (MD) simulations are a powerful tool to investigate such resistance mechanisms. Insights from MD simulations of receptor-ligand complex heavily depend on the quality of the parameters of the ligands. Thus, we developed and optimized CHARMM Force field parameters of enzalutamide. The initial assignment of parameters was done by using the CHARMM General Force Field (CGenFF) program. After that, using the Force Field Tool Kit (FFTK) partial charges, bond, angle and dihedral parameters of enzalutamide were optimized to reproduce quantum mechanics calculation results. For the validation of parameters, water-octanol partition coefficient, Infrared Spectra (IR) and normal mode analysis calculations were performed. In addition, a 300 ns-long MD simulation of enzalutamide was carried out to assess the ability of the optimized parameters in exploring torsional angle space.

Tanım

Dergi veya Seri

Journal of Molecular Graphics and Modelling

ISSN

1093-3263

ISBN

Haklar

OPEN

Anahtar Kelimeler

Male, Pharmaceutical Preparations, Benzamides, Nitriles, Phenylthiohydantoin, Humans, Prostatic Neoplasms, Molecular Dynamics Simulation, Ligands

Alıntı

Koleksiyonlar

Onay

Gözden geçir

Tamamlayıcı Bilgiler

Referans Gösteren

Related Patent

Related Goal

0
Görüntülenme
0
İndirme
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators
Google Scholar
Scholar'da Ara ↗